Kliniken & Institute ... Kliniken Chirurgische Klinik... General, Visceral and... Research Pankreasforschung Sektion... Molecular OncoSurgery ... Publications Original Articles 2004-2009

 

Salnikov AV, Groth A, Apel A, Kallifatidis G, Beckermann BM, Khamidjanov A, Ryschich E, Büchler MW, Herr I, Moldenhauer G (2009). Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma. J Cell Mol Med, 13, 4023-33.

 

Büchler P, Reber HA, Tomlinson J, Hankinson O, Kallifatidis, Friess H, Herr I, Hines OJ. (2009). Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia, 11 (2), 196-206. 

 

Apel A, Groth A, Bruns H, Schemmer P, Büchler MW, Herr I. (2009). Suitability of human mesenchymal stem cells for gene therapy depends on the expansion medium. Exp. Cell Res, 315, 498-507.

 

Salnikov A, Kusumawidjaja G, Rausch V, Bruns H, Gross W, Khamidjanov A, Ryschich E, Gebhard MM, Moldenhauer G, Büchler MW, Schemmer P, Herr I. (2009). Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic marker. Cancer Letters, 275, 185-193.

 

Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, Groth A, Mattern J, Li Z, Kolb A, Moldenhauer G, Altevogt P, Wirth T, Werner J, Schemmer P, Büchler MW, Salnikov AV, Herr I (2009). Sulforaphane targets pancreatic tumor-initiating cells by NF-kB-induced anti-apoptotic signaling. GUT, 58, 949-63. 

 

Beckermann B, Kallifatidis G, Groth A, Frommhold D, Apel A, Mattern J, Salnikov AV, Moldenhauer G, Wagner W, Diehlmann A, Saffrich R, Eckstein V, Schubert M, Ho A, Giese N, Büchler MW, Friess H, Büchler P, Herr I (2008). VEGF expression by mesenchymal stem cells contributes to angiogenesis of pancreatic carcinoma. Brit. J. Cancer, 99, 622-31. 

 

Kallifatidis G*, Beckermann B*, Groth A*, Schubert M*, Apel A, A. Khamidjanov, E. Ryschich, Wenger T, Wagner W, Diehlmann A, Saffrich R, Eckstein V, Krause U, Mattern J, Chai M, Schütz G, Ho A, Gebhard MM, Büchler MW, Friess H, Büchler P, Herr I (2008). Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancer, Cancer Gene Therapy, 15, 231-40. 
 


Apel A, Herr I, Büchler MW, Schwarz H, Rodemann HP and Mayer A (2008). Blocked autophagy sensitizes carcinoma cells to radiation therapy. Cancer Research, 68, 1485-1494.

 

Gaussmann A, Wenger T, Eberle I, Bursen A, Bracharz S, Herr I, Dingermann T and Marschalek R (2007). The two reciprocal t(4;11) fusion proteins, MLL.AF4 and AF4-MLL, confer resistance to apoptosis, provide cell cycling capacity and upregulate the pluripotency gene Nanog. Oncogene, 26, 3353-3363. 

 

Wenger T, Mattern J, Haas TL, Sprick MR, Walczak H, Friess H, Büchler MW, Debatin K-M and Herr I (2007). Transduction-dependent and independent induction of apoptosis by lentiviral TRAIL renders tumour therapy ineffective in vivo. Cancer Gene Therapy, 14, 316-326.

 

Zhang C, Wenger T, Mattern J, Ilea S, Frey C, Gutwein P, Altevogt P, Bodenmüller W, Gassler N, Schnabel PA, Dienemann H, Marmé A, Hohenfellner M, Haferkamp A, Pfitzenmaier J, Groene H-J, Kolb A, Büchler P, Büchler MW, Friess H,Rittgen W, Edler L, Debatin K-M, Krammer, PH, Rutz HP and Herr I (2007). Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol & Ther, 6, 278-287.  

 

El Fitori J, Su Y, Büchler P, Ludwig R, Giese NA, Büchler MW, Quentmeier H, Hines OJ, Herr I and Friess H (2007). PKC 412 – a small molecule tyrosine kinase inhibitor – as single compound therapy of pancreatic cancer. Cancer, 110, 1457-1468. 

 

Möller M, Herzer K, Wenger T, Krammer PH, Herr I and Wink M (2007). The plant alkaloid emetine as a new promising agent for induction and enhancement of drug-induced apoptosis in leukaemia cells. Oncol Rep, 18, 737-744.

 


Stoeck A, Schlich S, Issa J, Gschwend V, Wenger T, Herr I, Marme A, Bourbie S, Altevogt P, Gutwein P (2006). L1 on ovarian carcinoma cells is a binding partner for Neuropilin-1 on mesothelial cells. Cancer Letters, 239, 212-226. 

Zhang C, Kolb A, Mattern J, Gassler N, Wenger T, Herzer K, Krammer PH, Debatin KM, Büchler MW, Friess H and Herr I (2006). Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy. Cancer Letters, 242, 104-111. 

Zuliani C, Kleber S, Klussmann S, Wenger T, Kenzelmann M, Schreglmann N, Martinez A, del Rio JA, Soriano E, Vodrazka P, Kuner R, Groene H-J, Herr I, Krammer PH and Martin-Villalba A (2006). Control of neuronal branching by the death receptor CD95 (Fas/Apo-1). Cell Death and Differentiation, 1, 31-40. 

Zhang C, Mattern J, Haferkamp A, Pfitzenmaier J, Hohenfellner M, Rittgen W, Edler L, Debatin K-M, Groene E and Herr I(2006). Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol. Ther, 5, 59-64. 


Zhang C, Marme A, Wenger T, Gutwein P, Altevogt P, Debatin, K-M, Mattern, J and Herr I (2006). Glucocortidoid-mediated inhibition of chemotherapy in ovarian carcinomas. Int. J. Oncology, 28, 551. 

Zhang C, Kolb A, Büchler P, Cato A, Debatin K-M, Büchler MW, Friess H and Herr I (2006). Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer. BMC Cancer, 6, 61. 

Wenger T, Mattern J, Penzel R, Gassler N, Haas T, Sprick M, Walczak H, Krammer PH, Debatin K-M and Herr I (2006). Resistance by intracellular retention of TRAIL receptors by lentiviral TRAIL transfer. Cell Death and Differentiation, 13, 1740-1751. 

Zhang C, Gassler N, Schnabel PA, Dienemann H, Kolb A, Büchler MW, Friess H and Herr I (2006). A new tool for experimental tumour research. Oncology Reports, 5, 1153-1155. 

 

Zhang C, Beckermann B, Kallifatidis G, Liu Z, Rittgen W, Edler L, Büchler P, Debatin K-M, Büchler MW, Friess H and Herr I (2006). Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma. Int. J. Oncology, 29, 1295-1301. 


Gast D, Riedle S, Schabath H, Schlich S, Schneider A, Issa Y, Stoeck A, Fogel M, Joumaa S, Wenger T, Herr I, Gutwein P and Altevogt P (2005). L1 augments cell migration and tumor growth but not β3 integrin expression in ovarian carcinomas. Int. J. Cancer, 115, 658-665. 

Gassler N, Zhang C, Wenger T, Schnabel PA, Dienemann H, Debatin K-M, Mattern J and Herr I (2005). Dexamethasone-induced therapy resistance in lung carcinoma samples treated ex vivo. Brit. J. Cancer, 92, 1084-1088. 

Gassler N, Herr I, Schneider A, Penzel R, Langbein L, Schirmacher P, Kopitz J. (2005). Impaired expression of Acyl-CoA Synthetase 5 in sporadic colorectal adenocarcinomas and adenomas. J. Pathology, 18, 295-300.  

 

Mohr A, Henderson G, Dudus L, Herr I, Debatin K-M, Fisher K and Zwacka RM (2004). AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. Gene Therapy, 11, 534-543. 

Okouoyo S, Herzer K, Ucur E, Mattern J, Krammer, P, Debatin K-M and Herr I (2004). Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo. Int. J. Cancer, 108, 580-587 

Gassler N, Herr I, Keith M, Autschbach F, Schmitz-Winnenthal H, Ulrich A, Otto HF, Kartenbeck J and Z´graggen K (2004). Wnt-signalling and apoptosis after neoadjuvant short-term radiotherapy for rectal cancer. Int. J. Oncology, 25, 1543-1549. 

 

 zurück